BioRestorative Therapies Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

BioRestorative Therapies hat ein Gesamteigenkapital von $10.0M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $14.6M bzw. $4.6M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$13.09m
Eigenkapital	US$9.99m
Gesamtverbindlichkeiten	US$4.58m
Gesamtvermögen	US$14.57m

Jüngste Berichte zur Finanzlage

Recent updates

BioRestorative begins enrollment in mid-stage study of stem cell therapy for lumbar disk disease

Jun 30

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: BRTXDie kurzfristigen Aktiva des Unternehmens ($13.5M) übersteigen seine kurzfristigen Passiva ($4.6M).

Langfristige Verbindlichkeiten: BRTX hat keine langfristigen Verbindlichkeiten.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: BRTX ist schuldenfrei.

Schulden abbauen: BRTX ist derzeit schuldenfrei, aber wir können keinen Vergleich mit dem Zeitraum vor 5 Jahren anstellen, da uns keine Daten für diesen Zeitraum vorliegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: BRTX auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: BRTX verfügt über eine ausreichende Liquiditätsreserve für 1.4 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 6.2% pro Jahr abnimmt.

BioRestorative Therapies Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice Due to Failure to Timely File its Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice Due to Failure to Timely File its Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

BioRestorative Therapies, Inc. announced delayed 10-Q filing

BioRestorative Therapies, Inc. announced delayed annual 10-K filing

First Amended Joint Reorganization Plan and Disclosure Statement Filed by BioRestorative Therapies, Inc.

Interim DIP Financing Approved for BioRestorative Therapies, Inc.

Recent updates

Consensus revenue estimates decrease by 17%, EPS upgraded

New major risk - Revenue and earnings growth

BioRestorative Therapies, Inc. Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data

BioRestorative Therapies, Inc. has filed a Follow-on Equity Offering in the amount of $3.61417 million.

BioRestorative Therapies, Inc. Receives Expanded Tissue License from New York State Department of Health

Consensus revenue estimates increase by 72%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

BioRestorative Therapies, Inc., Annual General Meeting, Sep 19, 2024

BioRestorative Therapies, Inc. to Report Q2, 2024 Results on Aug 13, 2024

BioRestorative Therapies, Inc. Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice Due to Failure to Timely File its Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice Due to Failure to Timely File its Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

BioRestorative Therapies, Inc. announced delayed 10-Q filing

BioRestorative Therapies, Inc. Enhances Preclinical Metabolic Program with A Novel Exosome-Based Biologic Targeting Obesity

BioRestorative Therapies, Inc. to Report Q1, 2024 Results on May 14, 2024

Consensus revenue estimates increase by 20%, EPS downgraded

BioRestorative Therapies, Inc. Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease

Consensus EPS estimates upgraded to US$1.96 loss

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Consensus revenue estimates increase by 12%

BioRestorative Therapies Presents Promising Data At Orthopaedic Research Society 2024 Annual Meeting

BioRestorative Therapies, Inc. Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 105%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

BioRestorative Therapies, Inc., Annual General Meeting, Sep 13, 2023

Biorestorative Therapies Inc. Receives License from New York State

BioRestorative Therapies, Inc. announced that it expects to receive $2.07565 million in funding

BioRestorative Therapies, Inc. Receives Unanimous Recommendation to Proceed in Its Phase 2 Clinical Trial for Chronic Lumbar Disc Disease, BRTX-100

BioRestorative Therapies, Inc. Receives Notice of Allowance by the Japanese Patent and Trademark Office for Patent Application Related to Its Thermostem Program

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Phase 2 Clinical Trial

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Biorestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to Its Thermostem(R) Program

BioRestorative Therapies Inc. Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem Targeting Polycystic Ovary Syndrome as an Indication

Third quarter 2022 earnings released: US$1.28 loss per share (vs US$4.99 loss in 3Q 2021)

High number of new and inexperienced directors

BioRestorative Therapies, Inc., Annual General Meeting, Nov 03, 2022

BioRestorative Therapies, Inc. Announces First Patient Enrolled for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

BioRestorative begins enrollment in mid-stage study of stem cell therapy for lumbar disk disease

Biorestorative Therapies, Inc. Announces Clinical Trial Contract with Second Site for the Company’S Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (Cldd)

BioRestorative Therapies Announces Clinical Site Initiation for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

BioRestorative Therapies, Inc. Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

Biorestorative Therapies Announces It Has Initiated Its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease – Site Selection Underway

BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio

BioRestorative Therapies, Inc. Announces Filing of Ten Patent Applications Related to its BRTX-100 Program

BioRestorative Therapies, Inc. Receives Notice of Allowance for Patent Application in Israel for Its Metabolic Program

BioRestorative Therapies Receives Patent in Japan Related to its Off-the-Shelf ThermoStem® Program

BioRestorative Therapies, Inc. announced delayed annual 10-K filing

Biorestorative Therapies, Inc. Elects Nickolay Kukekov as Director

BioRestorative Therapies, Inc. Announces Board Changes

BioRestorative Therapies, Inc. announced that it has received $0.6 million in funding

First Amended Joint Reorganization Plan and Disclosure Statement Filed by BioRestorative Therapies, Inc.

Interim DIP Financing Approved for BioRestorative Therapies, Inc.

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen